White matter and its relationship with cognition in subjective cognitive decline
| dc.contributor.author | Ohlhauser, Lisa | |
| dc.contributor.author | Parker, Ashleigh F. | |
| dc.contributor.author | Smart, Colette M. | |
| dc.contributor.author | Gawryluk, Jodie R. | |
| dc.contributor.author | for the Alzheimer’s Disease Neuroimaging Initiative | |
| dc.date.accessioned | 2019-01-17T18:12:52Z | |
| dc.date.available | 2019-01-17T18:12:52Z | |
| dc.date.copyright | 2019 | en_US |
| dc.date.issued | 2019 | |
| dc.description.abstract | Introduction: Subjective cognitive decline (SCD) is the earliest stage on the continuum toward Alzheimer's disease. This study examined (1) differences in white matter integrity between individuals with SCD and healthy control subjects and (2) how white matter integrity related to memory and executive function. Methods: Diffusion tensor imaging and neuropsychological assessment data were retrieved from the Alzheimer's Disease Neuroimaging Initiative database for 30 individuals with SCD and 44 control subjects. Results: Results revealed significantly lower white matter integrity in individuals with SCD relative to control subjects in widespread regions, including the bilateral corticospinal tracts, superior and inferior longitudinal fasciculi, fronto-occipital fasciculi, corpus callosum, forceps major and minor, hippocampi, anterior thalamic radiations, and the cerebellum. There was a widespread relationship between diffusion tensor imaging metrics and executive function in SCD, but not healthy control subjects, and no relationship with memory for either group. Discussion: Relatively lower white matter integrity in SCD may be a useful early biomarker for risk of future cognitive decline. Future research should better characterize the SCD group longitudinally and in individuals at risk for Alzheimer's disease. | en_US |
| dc.description.reviewstatus | Reviewed | en_US |
| dc.description.scholarlevel | Faculty | en_US |
| dc.description.sponsorship | Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Funding for secondary analyses of the ADNI database was provided by a Catalyst Grant from the Canadian Institute for Health Research. | en_US |
| dc.identifier.citation | Ohlhauser, L., Parker, A.F., Smart, C.M., Gawryluk, J.R. & Alzheimer’s Disease Neuroimaging Initiative (2019). White matter and its relationship with cognition in subjective cognitive decline. Alzheimer’s & Dementia, 11, 28-35. https://doi.org/10.1016/j.dadm.2018.10.008 | en_US |
| dc.identifier.uri | https://doi.org/10.1016/j.dadm.2018.10.008 | |
| dc.identifier.uri | http://hdl.handle.net/1828/10523 | |
| dc.language.iso | en | en_US |
| dc.publisher | Alzheimer’s & Dementia | en_US |
| dc.subject | Subjective cognitive decline | |
| dc.subject | Diffusion tensor imaging | |
| dc.subject | Executive function | |
| dc.subject | Memory | |
| dc.subject | Alzheimer's disease | |
| dc.subject.department | Department of Psychology | |
| dc.title | White matter and its relationship with cognition in subjective cognitive decline | en_US |
| dc.type | Article | en_US |